Kornimate/medical-research-clean huggingface dataset:
role of gait analysis in different type of dementia

Conditions: Dementia; Gait Analysis

Summary: aim for the work is the studying of the existence and pattern of gait impairment in pre-dementia and dementia to examine the association between dual decline in gait and cognition

dementia is a syndrome usually chronic,characterised by progressive global deterioration in intellect, including memory,learning,orientation,comprehension,judgment,gait, and balance gait and balance are the product of successful integration of various posture control mechanisms and locomotion. there are two basic phases in the full cycle of the step stance phase swing phase slow gait speeds are associated with both cognitive decline and greater risk of dementia so, our aim of this work is to study the existence and pattern of gait balance impairment in patients with different types of dementia and comparison with healthy elderly people.

Eligibility criteria:
inclusion criteria: * patients with pre-dementia,dementia, and dementia diagnosed according to the vascular behaviour and cognitive disorder (vascog) and on medication criteria attending assiut university neurology outpatient clinic and internal department exclusion criteria: * 1 history of clinic manfist cerebrovascular stroke 2 definitely laterization sign 3 severe cognitive imparment moca 4 spinal or orthopaedic problems 5 long-term use or abuse of medication affect cognition or balance 6 clinical evidence of peripheral neuropathy

Keywords: dementia gait analysis prognosis
escitalopram and depression in elderly alzheimer's patients

Conditions: Depressive Disorder

Summary: to investigate the effect of escitalopram in a large and diverse of dementia patients suffering from depression.

this study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of major depressive disorder in patients with alzheimer's disease over a 24-week period. it will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Eligibility criteria:
inclusion criteria: * \> 50 years * male \& female * alzheimer's disease * depressive episode

Keywords: alzheimer's disease elderly open-label escitalopram
the intensively follow-up examinations for asymptomatic mps i infants in taiwan

Conditions: MPS I

Summary: mps i newborn screening has been executed in taiwan nationwide since august 2015. infants who failed the recheck at recall were referred to mackay memorial hospital for a detailed confirmatory diagnosis. urinary first-line biochemistry examinations including urinary gag quantification (dmb/cre. ratio), two-dimensional electrophoresis (2-d ep), and tandem mass spectrometry assay for predominant disaccharides derived from gags (i.e. cs, ds, hs, and ks) were performed. if the results were positive, a confirmative diagnosis was made according to the results of leukocyte enzymatic assay and molecular dna analysis. up to january 31, 2019, a total of 390,793 infants had been analyzed for mps i, in those 11 suspicious cases were referred to mackay memorial hospital for confirmation. the recall rates of mps i was 0.0028%. four of the 11 infants were confirmed to have mps i. the prevalence rates of mps i was 1.02 per 100,000 live births, respectively. infants suspected of having mps with a positive laboratory diagnosis but without any typical, clinical manifestations are not conformed to receive ert under the treatment guideline of ert for mps in taiwan. distinctly, the clinical manifestations of mps are irreversible and would be worse progressively while the symptoms have shown up. receiving ert at this time would effectively prevent the progression of illness, but, cannot rescue or reform the irreversible physical problems. by proceeding and undergoing an intensively long-term regular physical and laboratory examinations for asymptomatic infants with mps i can effectively control the possibility of giving an ert in a timely fashion.

the study hypothesis is to proceed and to undergo an intensively long-term clinical management and laboratory examinations for asymptomatic infants with mps i in order to be able to give an enzyme replacement therapy (ert) in a timely fashion. the overall objectives of this study are summarized as follows, including: 1. to plan a three-month or six-month interval of recall process depending on the judgment of individual case by pediatric geneticist. 2. to recall the asymptomatic mps i infants back to mackay memorial hospital for mps follow-up examinations, including regular physical examinations for the earliest presenting symptoms such as otitis media, abdominal or inguinal hernia, and coarse facial features, as well as the urinary biochemistry glycosaminoglycan (gag) tests. 3. to give ert in time whenever the typical mps signs or symptoms showed up. 4. to achieve the aim of newborn screening for mps, "early detection, making early diagnosis, and providing early therapy can effectively prevent the development of severe clinical manifestations".

Eligibility criteria:
inclusion criteria: * the confirmed mps i infants exclusion criteria: * not mps i infants

Keywords: mps i
prostate specific membrane antigen pet/ct imaging in psma-related disease patients

Conditions: PSMA-related Disease; Prostate Cancer; Positron Emission Tomography; Metastasis; FAP

Summary: to evaluate the potential usefulness of 68ga/18f-psma/psfa positron emission tomography/computed tomography (pet/ct) for the diagnosis of primary and metastatic lesions in various psma-related disease patients.

subjects with various psma-related disease patients underwent 68ga/18f-psma/psfa pet/ct either for an initial assessment or for recurrence detection. lesions uptake was quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv) and accuracy of 68ga/18f-psma/psfa pet/ct were calculated.

Eligibility criteria:
inclusion criteria: - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include mri, ct, tumor markers and pathology report); (iii) patients who had scheduled psma pet/ct scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: pet/ct psma fap
long term outcomes of vivity intra ocular lens(iol) versus control

Conditions: Cataract

Summary: evaluate the long-term (\>1 yr) outcomes of the vivity iol. the investigator will use similar measurements and procedures to the ones performed on these subjects during the fda clinical trial.


Eligibility criteria:
inclusion criteria: must have participated in the fda study at one of the included sites exclusion criteria: none
role of subsequent atrial tachycardia in mechanisms of persistent af

Conditions: Atrial Fibrillation

Summary: in this study, the investigators aim to examine the prognostic role of subsequent atrial tachycardias (ats) in the mechanisms of atrial fibrillation (af). therefore, the investigators compare patients who were randomly assigned to either undergo cardioversion after af has been terminated to at or further ablation until the achievement of sinus rhythm.


Eligibility criteria:
inclusion criteria: * persistent af for at least 1 months, * age \> 18 years, * refractory to drug therapy, * no prior ablation exclusion criteria: * prior af ablation

Keywords: atrial fibrillation catheter ablation subsequent atrial tachycardia mechanisms
dose-reduced allogeneic stem cell transplantation after autologous high-dose chemotherapy in patients with multiple myeloma

Conditions: Multiple Myeloma; Stem Cell Transplantation

Summary: to evaluate the feasibility and efficacy of a autologous stem cell transplantation followed by a melphalan/ fludarabine based dose-reduced allograft from hla-identical and hla-compatible unrelated donor in patients with multiple myeloma. in those with non complete remission dli and/ or new agents such as bortezomib, thalidomid or lenalidomide can be used to upgrade remission.


Eligibility criteria:
inclusion criteria: * multiple myeloma stadium ii / iii acc. to salmon and durie * signed informed consent * adequate organ function prior autologous respectively allogeneic sct * availability of hla-identical related or unrelated donor * availability of at least 2 x 10\^6 cd34+ cells per kg bw of recipient for the autologous sct and at least 3 x 10\^6 cd34+ cells for allogeneic sct * for mrd-sct: 18-66 years; for mud-sct: 18-55 years * at age \<55 years existence of risk factors that make an myeloablative allogeneic transplantation to risky * consent of donor to give dli exclusion criteria: * severe heart insufficiency * cardiovascular diseases or severe concomitant diseases * active infections that need antibiotic therapy * positive for hiv or hepatitis * malign secondary disease * limited liver function with total bilirubin \> 1.5 uln * increased transaminase \> 3 uln * increased serum creatinine \> 2 mg/dl * pregnant or lactating women * known hypersensitivity to fludarabine or melphalan * participation in another trial

Keywords: multiple myeloma plasmocytoma stem cell transplantation
appropriate laryngeal mask airway size in patients with overweight: a comparison of the actual body weight and ideal body weight

Conditions: General Anesthesia

Summary: the classic laryngeal mask airway is one of the keystones of modern anaesthetic practice. it achieves a reliable airway with a low incidence of major complications and pharynges-laryngeal morbidity. the manufactures of laryngeal mask airway recommend the proper size selection by actual body weight. it was recommended a size 3 for 30-70kg, a size 4 for 70-90 kg, and size 5 for \> 90 kg. obesity increases the fat tissue around an upper airway and decreases the pharyngeal cross sectional area. also it was reported that pharyngeal area was reduced according to the increasing of bmi. therefore, the aim of this study is to determine which of actual body weight or ideal body weight is proper on the size selection of laryngeal mask airway.


Eligibility criteria:
inclusion criteria: * age 20\~70 * body mass index \> 25 kg/m2 * patient who needs surgery with laryngeal mask airway exclusion criteria: * difficult airway * upper airway infection or disease of airway * history of gastroesophageal reflux * history of head and neck surgery

Keywords: general anesthesia body weight laryngeal mask airway size
danshu capsule and ursodeoxycholic acid capsule in preventing recurrence of choledocholithiasis

Conditions: Choledocholithiasis; Recurrence

Summary: \[objective\] to compare the efficacy of danshu capsule and ursodeoxycholic acid (udca) in preventing recurrence of choledocholithiasis after operation. \[methods\] one hundred and fifty ercp patients with choledocholithiasis were randomly divided into two groups: danshu group (n = 75) and udca group (n = 75). the danshu group took 2 danshu capsules three times a day, and the udca group took 250 mg of ursofalk twice a day. the clinical efficacy, changes of liver function indexes before and after treatment and stone recurrence were compared between the two groups.


Eligibility criteria:
inclusion criteria: 1. choledocholithiasis was diagnosed by b-ultrasound / ct/mrcp, the patients are generally in good condition, no surgical taboos, and can tolerate general anesthesia and ercp surgery. 2. agree to participate in the project research, know the benefits and possible risks of surgery, know the benefits and risks of drugs, and sign an informed consent form. exclusion criteria： 1. patients with cholecystolithiasis, hepatitis b, biliary ascariasis, liver cirrhosis, hemolytic anemia, congenital jaundice and tumor were excluded. 2. excluding serious primary diseases such as heart, brain, lung, kidney and blood system. 3. those who are allergic or allergic to drugs in this test are excluded. 4. pregnancy vibration or nursing women were excluded.
comparing pre-mixed insulin with insulin glargine combined with rapid-acting insulin in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to compare lispro mixture therapy (insulin lispro 50/50 given three times daily with meals) to glargine basal-bolus therapy (insulin glargine daily with the addition of insulin lispro given three times daily with meals). the study is also comparing two different methods for adjusting the dose of insulin.


Eligibility criteria:
inclusion criteria: * must have type 2 diabetes. * must be 30-75 years of age at the time of visit 1. * must be on insulin glargine and oral antidiabetic medicines for at least 90 days. * must be on at least 30 units of glargine per day at enrollment. * have an a1c between 7.5% and 12.0% at visit 1. exclusion criteria: * must not have used rapid/short-acting insulin on a regular basis in the last 6 months. * must not have more than one episode of severe hypoglycemia in the last 6 months. * must not have a body mass index (bmi) of greater than 45 (morbid obesity). * must not have congestive heart failure that requires medications. * must not have had a kidney transplant or currently receiving dialysis
dural graft equivalent comparison trial

Conditions: Chiari Malformation

Summary: this research study is to find out which types of dural grafts used during surgery for chiari malformations are superior. we believe that autologous dural grafts are superior to non-autologous grafts.

the study compares autologous grafts vs. non-autologous grafts. non-autologous grafts include synthetics and grafts from animals. autologous grafts have a better side-effect profile than non-autologous grafts. we believe this improved side-effect profile will result in a decreased incidence of reoperation for post-operative infections and post-operative fluid collections (pseudomeningoceles and seromas). study is open to all non-pregnant minor and adult subjects. subjects must have symptomatic chiari malformation described as \> or equal to 6mm descent of the cerebellar tonsils below the foramen magnum with accompanying headaches and/or neurologic findings (arm pain/weakness, myelopathy, etc.). after the 12-month follow-up is completed on the first 100 subjects there will be an interim analysis of the results in order to determine whether one of the treatments has a statistically superior outcome. if a statistically superior outcome is noted, the trial will stop after being reviewed by a data monitoring committee. if no statistically significant difference is seen at one year, the study will continue until the 12-month follow-up is completed on the 200th patient.

Eligibility criteria:
inclusion criteria: * minor or adult males and females * symptomatic chiari malformation * greater or equal to 6mm descent of the cerebellar tonsils below the foramen magnum * headaches and/or neurologic findings (e.g., arm pain/weakness, myelopathy, etc.) exclusion criteria: * pregnancy
lactate kinetics in septic shock

Conditions: Sepsis; Septic Shock

Summary: lactate kinetics will be studied in hospitalized septic patients using a bolus injection of stable isotopically labeled lactate.

adult septic patients admitted to the intensive care unit (icu) or intermediary medical unit in karolinska university hospital will be recruited within 72 hours from start of symptoms. other than fulfilling the definition for sepsis-3, patients need to be equipped with an arterial catheter to be eligible for inclusion. after informed consent (from next of kin when applicable) baseline blood samples are drawn from existing catheter and the subject is given a bolus dose of 20umol/kg 13c-labeled lactate in 20 ml isotonic saline. after this a total of 14 blood samples á 2 ml is drawn in the following 120 minutes. all blood samples are centrifuged and stored in -800 c until analysis. after all subjects have been included sampled are thawed and analyzed for content of endogenous and labeled lactate. through analysis between their relationship the lactate production and consumption can be quantified.

Eligibility criteria:
inclusion criteria: * sepsis * age \>17 years * arterial catheter * lactate \> 2 mmol at any time point prior to inclusion exclusion criteria: * mitochondrial defect * degenerative muscle disease * terminal liver failure
a scoring system for difficult laparoscopic cholecystectomy

Conditions: Cholecystitis, Chronic

Summary: laparoscopic cholecystectomy is the treatment of choice for gall bladder stone disease. difficult laparoscopic cholecystectomy (lc) is the most common "difficult" surgical procedure performed today, which possesses the potential to place the patient at significant operative risk.the aim of this study was to put a scoring system to avoid difficult laparoscopic cholecystectomy.

patients with symptomatic chronic calculous cholecystitis based on clinical and radiological correlation undergoing elective laparoscopic cholecystectomy at assiut university hospitals will be included for the study of 100 patients will operated by single experienced laparoscopic surgeon.the scores are given on history, clinical examination and radiological findings one day prior to surgery on admission.

Eligibility criteria:
inclusion criteria: * adults male and female age of or above 18 years * symptomatic chronic calculous cholecystitis * ultrasound confirmed gall bladder stones exclusion criteria: * complicated chronic calculous cholecystitis * malignant gall bladder
a multi-center survey of hpv in cervical intraepithelial neoplasia (cin) with longitudinal follow-up of lsil cases

Conditions: Cervical Cancer; Low-grade Squamous Intraepithelial Lesion,; Human Papillomavirus

Summary: the aims of this study are: 1. surveillance of the prevalence of hpv infection in ascus, agcus and sil cases pooled from medical centers in taiwan and analysis of the related epidemiological factors. 2. providing a better understanding of the natural history of hpv infection with its correlation with pathologic changes through a longitudinal follow-up of lsil cases.

carcinoma of the uterine cervix is by far the most prevalent cancer of women in taiwan and worldwide. in 1994, it ranked the top of female cancer incidence with 3000 new cases annually and claimed nearly 1000 lives. the major cause of this malignant disease is now pointed to the infection of oncogenic types of human papillomavirus (hpv). hpv infection is sexually transmitted, affects the immature metaplastic cells of uterine cervix and, in an unknown proportion, results in squamous intraepithelial lesion (sil) of differing severity. the natural history of hpv infection is by far elusive. it is not clear how the virus get into the cell, how the immune system respond to it, and how the epithelial cell get transformed. an average estimation holds that about 60% of low grade sil will regress, 30% will persist, 10% will progress to high grade lesions and less than 1% become invasive lesions. the aims of this study are: 1. surveillance of the prevalence of hpv infection in ascus, agcus and sil cases pooled from medical centers in taiwan and analysis of the related epidemiological factors. 2. providing a better understanding of the natural history of hpv infection with its correlation with pathologic changes through a longitudinal follow-up of lsil cases. through a consensus of management of patients with abnormal pap smear in tgog, a standard protocol of specimen collection, clinical follow-up has been established. patients with a pap smear of ascus, agcus or sil will be arranged with a repeat pap smear and a colposcopy with or without biopsy. a cervical swab will be taken and sent to the core laboratory for hpv dna detection and genotyping. pap smear and biopsies were then panel-reviewed by pathologists. cytology-or pathology-proved lsil cases will be followed every three months with pap smear, colposcopy and hpv test until disease progression or two consecutive negative results of all the three data. one thousand cases fulfilling "aim 1" will be analyzed during the first year, and the nature course of about 300 lsil cases will be followed at the end of the third year.

Eligibility criteria:
inclusion criteria: * women visiting the gynecologic clinic of the participating medical centers and have a recent (within three months) pap smear result of ascus, agcus, lsil and hsil of during the study period will be invited to this study. * an informed consent signed. exclusion criteria: - women who are not pregnant, had had no previous cin

Keywords: cervical neoplasia; human papillomavirus, pcr, risk factors, taiwan
physical exercise and cognitive engagement outcomes for mild neurocognitive disorder

Conditions: Mild Cognitive Impairment; Memory Disorders; Mild Dementia; Impaired Cognition; Mild Cognitive Disorder; Amnestic Disorder; Dementia and Amnestic Conditions; Poor Short-term Memory; Memory Impairment; Mild Neurocognitive Disorder

Summary: behavioral interventions currently provide the most useful approach to addressing the behavioral and social needs of those with mild cognitive impairment (mci) due to alzheimer's or other diseases. this randomized, multisite, 3-arm study will investigate the impact of computerized brain fitness vs yoga vs an active control group (wellness education) on changes in cognitive function, daily functioning and quality of life in persons with mild cognitive impairment (mci) and their partner. in addition, in vivo neuroimaging measures of plasticity during the pre- and post-intervention periods will be measured and compared between the three different treatment groups. these neuroimaging measures of plasticity will be investigated in their relationship to the cognitive outcomes within each group.


Eligibility criteria:
for the patients diagnosed with mci: inclusion criteria: 1. written informed consent for participation. patient also needs to sign a legally authorized representative (lar) addendum should mci patient become incapacitated 2. a diagnosis of amnestic mci (single domain or multi-domain) 3. a clinical dementia rating scale score of 0 or 0.5 4. at least 50. 5. either not taking or stable on nootropic(s) and/or pain medication for at least 3 months. 6. fluent in english. 7. a score of at least 25 on the telephone interview for cognitive status for memory. exclusion criteria: 1. mri contraindications (e.g., ferrous metal in the body, claustrophobia, pregnancy) 2. physical impairments, language comprehension deficits, or significant hearing disturbances that would limit ability to perform tasks or participation in the intervention. for the care partners: inclusion criteria: 1. written informed consent for participation. 2. at least 21 years of age. 3. a score of at least 32 on the telephone interview for cognitive status for memory. 4. partner has at least twice-weekly contact with the participant. exclusion criteria: 1. physical impairments, language comprehension deficits, or significant hearing disturbances that would limit ability to perform tasks or participation in the intervention.